All crystal structures of the TCR β chain reported to date have shown that the constant and variable domains are closely associated, with a large, solvent-exposed loop of 14 amino acids protruding on the external face of the Cβ domain [1](#R1){ref-type="bib"} [2](#R2){ref-type="bib"} [3](#R3){ref-type="bib"} [4](#R4){ref-type="bib"}. The location and size of this loop (almost half of an Ig domain) suggested that it could be the crucial link between TCR-α/β recognition of antigen and transmission of signals by the invariant CD3 [1](#R1){ref-type="bib"} [4](#R4){ref-type="bib"} [5](#R5){ref-type="bib"}. To study its function, we recently generated mice transgenic for a TCR β chain lacking the complete Cβ FG loop. The TCR β chain (Vβ8.2-Jβ2.1) chosen for mutagenesis has been crystallized [1](#R1){ref-type="bib"}; it was cloned from T cell hybridoma 14.3.d, which expresses a TCR α chain (Vα4-Jα47) and recognizes a PR8 influenza hemagglutinin peptide, HA 110--119, presented by the I-E^d^ MHC molecule [6](#R6){ref-type="bib"}. Surprisingly, we found that development and function of conventional α/β T cells was normal in mice transgenic for a TCR β chain lacking the Cβ FG loop. Thus, the Cβ FG loop is not absolutely required for transmitting the signal of antigen recognition by the TCR [7](#R7){ref-type="bib"}.

Further analysis revealed that a small population of α/β T cells coexpressing NK1.1 is drastically diminished in these mice. Many features [8](#R8){ref-type="bib"}, including development, functional properties, and TCR repertoire, distinguish this latter population from conventional T cells. Development of NK1.1 T cells requires expression of the β~2~ microglobulin--associated, class Ib--like CD1d1 molecule [9](#R9){ref-type="bib"} [10](#R10){ref-type="bib"}, which can restrict their response to lipid ligands such as glycosylphosphatidylinositols or glycosylceramides [11](#R11){ref-type="bib"} [12](#R12){ref-type="bib"}. NK1.1 T cells can readily produce large amounts of cytokines upon activation [13](#R13){ref-type="bib"}, and they have been implicated in tumor rejection [14](#R14){ref-type="bib"} [15](#R15){ref-type="bib"} and may also play a regulatory role in autoimmune manifestations [16](#R16){ref-type="bib"} [17](#R17){ref-type="bib"} [18](#R18){ref-type="bib"}. NK1.1 T cells express a limited Vβ repertoire highly skewed toward Vβ8.2, Vβ7, and Vβ2 [8](#R8){ref-type="bib"}, and in transgenic mice expressing single Vβs such as Vβ3 and Vβ8.1, NK1.1 T cell development is totally abrogated [19](#R19){ref-type="bib"}. Furthermore, ∼80% of NK1.1 T cells express an invariant TCR α chain (Vα14-Jα281) [20](#R20){ref-type="bib"} [21](#R21){ref-type="bib"} that is required for their development [15](#R15){ref-type="bib"}.

In this study, we present evidence that the Vβ8.2 TCR β chain lacking the complete Cβ FG loop cannot pair efficiently with the canonical Vα14^+^ TCR α chain. Consequently, NK1.1 T cell development is severely impaired.

Materials and Methods
=====================

TCR-β Mutagenesis.
------------------

The wild-type TCR β chain (Vβ8.2-Jβ2.1) cDNA was used as a template for mutagenesis. Deletion of the 14 nucleotides forming the Cβ FG loop has been described [7](#R7){ref-type="bib"}. Transgenic vectors have also been described previously [22](#R22){ref-type="bib"}.

Transfection of Cell Lines.
---------------------------

Packaging cell lines GP+E-86 [23](#R23){ref-type="bib"} were transfected with retroviral vector LXSN expressing the Vβ8.2-Jβ2.1^+^ TCR-β or β-loop^−^ chain or LXSP expressing the Vα4-Jα47^+^ or Vα14-Jα281^+^ TCR α chain cDNA. The TCR α chain (Vα14-Jα281) was cloned from NK1.1 α/β^+^ T cell hybridoma total RNA provided by R. MacDonald (Ludwig Institute for Cancer Research, Lausanne, Switzerland). After appropriate selection of the packaging cells, the infectious supernatants were used to infect TCR^−^ hybridomas [24](#R24){ref-type="bib"} as previously described [25](#R25){ref-type="bib"}. The TCR-β or β-loop^−^ chain was first introduced into the hybridomas and, after neomycin selection (G418; 1 mg/ml), these cells were superinfected with TCR α chain by culturing them on packaging lines producing LXSP TCR-α Vα4-Jα47 or Vα14-Jα281. The hybridomas were then maintained in IMDM supplemented with 2% FCS, neomycin, and puromycin (10 μg/ml). TCR expression was tested by FACS™ as early as 4 d after selection. Stable transfectants were maintained in G418 and puromycin-containing medium.

TCR Immunoprecipitation and Western Blot Analysis.
--------------------------------------------------

Hybridomas were lysed at 2 × 10^7^ cells/ml in 1% Triton X-100 (Bio-Rad Labs.), 150 mM NaCl, 20 mM Tris/HCl, and 5 mM EDTA, pH 7.5, buffer containing complete protease inhibitors (Boehringer Mannheim) for 30 min at 4°C. Lysates cleared of cell debris were immunoprecipitated with purified mAb F23.1 (2 μg/ml) and protein G--Sepharose (Pharmacia). After washing with lysis buffer and PBS, the lyophilized pellets were resuspended in reducing SDS buffer, loaded on a 4--12% Bis-Tris precast gel (Novex), and transferred onto nitrocellulose membrane Hybond-C extra (Amersham). Blots were probed in PBS 6% blotting blocker nonfat milk (Bio-Rad Labs.) and 0.2% Tween with purified mAb H58 (anti-Cα), followed by goat anti--hamster horseradish peroxidase--labeled mAb (Southern Biotechnology Associates, Inc.) or biotinylated F23.1 (anti-Vβ8) mAb followed by streptavidin--horseradish peroxidase (Southern Biotechnology Associates, Inc.). The proteins were detected with a chemiluminescent detection system (Pierce Chemical Co.).

Mice.
-----

BALB/c and C56BL/6 mice were purchased from IFFA-Credo. The TCR-β knockout mice have been described [26](#R26){ref-type="bib"} and were bred in our specific pathogen--free animal facility with the TCR-β or TCR β-loop^−^ transgenic mice.

Cell Suspension, Flow Cytometry, and Antibodies.
------------------------------------------------

Cell suspensions from thymi were depleted of CD8^+^ T cells with anti-CD8 31M antibody [27](#R27){ref-type="bib"} and complement treatment (Cedarlane Labs.), and liver cells were simply ficolled to eliminate red cells before immunofluorescence stainings, performed as previously described [28](#R28){ref-type="bib"}. Flow cytometric analyses were performed on a FACSCalibur™ equipped with CELLQuest software (Becton Dickinson). The reagents used were mAbs 145-2C11 (anti-CD3∈), NKR-P1C (anti-NK1.1), H57-597 (anti-Cβ), RM4-5 (anti-CD4), IM7 (anti-CD44, Pgp-1), TM-β1 (anti--IL-2R β chain), MEL-14 (anti-CD62L) (all seven mAbs purchased from PharMingen), biotinylated F23.1 (anti-Vβ8.1,2,3), and second step reagent streptavidin--allophycocyanin (Molecular Probes, Inc.).

Single-Cell Reverse Transcriptase--PCR.
---------------------------------------

Single NK1.1^+^CD3^+^ cells were sorted into polycarbonated 96-well plates (one cell per well in 5 μl of PBS) and immediately frozen on dry ice and stored at −70°C. To prepare cDNA, the plate was heated up to 65°C for 1 min before adding into each well 10 μl of the reverse transcriptase (RT)-PCR mix (reverse transcriptase Superscript II; GIBCO BRL) for 1 h at 42°C under standard reaction conditions. After heat inactivation of the enzyme (2 min at 95°C), DNA amplification was carried out as described [29](#R29){ref-type="bib"}. 75 μl of a PCR mix containing Taq polymerase and the primers necessary for DNA amplification of the Vα14^+^ TCR α chain (5′ Vα14 CTAAGCACAGCACGCTGCACA \[reference 20\]; 3′ Cα ATGGATCCTCAACTGGACCACAGCCTCA) and Vβ8.2^+^ TCR β chain (5′ Vβ8.2 CTTGAGCTCAAGATGGGCTCCAGGCTCTTC; 3′ Jβ2.1 CTGCTCAGCATAACTCCCCCG) were added to the wells for the first round of PCR (30 cycles). An aliquot from this PCR (1 μl) was used for a second round of PCR (35 cycles) to individually reamplify the Vα14^+^ TCR α chain or Vβ8.2^+^ TCR β chain using the same specific primers.

Results and Discussion
======================

To avoid any influence of the endogenous β locus on the expression of the mutated β chain, mice transgenic for the Vβ8.2^+^ TCR β chain lacking the Cβ FG loop (β-loop^−^) were backcrossed to TCR-β^−/−^ mice [26](#R26){ref-type="bib"}. T cell development in these mice was compared with that in wild-type Vβ8.2^+^ TCR β chain transgenic mice, also with a β^−/−^ background. As described in our previous study [7](#R7){ref-type="bib"}, peripheral T cells from mice transgenic for the TCR β or β-loop^−^ chain express equal levels of the TCR--CD3 complex, and whereas the anti-Vβ8 F23.1 mAb recognizes all T cells, the Cβ-specific H57 mAb does not stain cells expressing the TCR β-loop^−^ chain ([Fig. 1](#F1){ref-type="fig"}; reference 4). It is worth pointing out that in the absence of the Cβ FG loop, the anti-CD3∈ 2C11 mAb stains better, suggesting that the epitope recognized is more accessible, a result that might not be surprising, as one of the CD3∈ chains is physically adjacent to the β chain in the TCR--CD3 complex [5](#R5){ref-type="bib"}.

We consistently found that TCR β-loop^−^ transgenic mice have significantly fewer NK1.1 α/β^+^ T cells in the thymus, liver, and spleen (data not shown) in comparison to TCR-β transgenic mice or wild-type littermates ([Fig. 2](#F2){ref-type="fig"}). Thus, a mutation in the Cβ domain can notably alter development of NK1.1 α/β T cells. This result was puzzling, considering that conventional α/β T cells are normal in TCR β-loop^−^ transgenic mice [7](#R7){ref-type="bib"}. Furthermore, the mutated TCR β chain uses Vβ8.2, a variable region that is usually expressed by \>40% of NK1.1 α/β T cells [30](#R30){ref-type="bib"}. Hence, monoclonal expression of the wild-type Vβ8.2^+^ TCR β chain allows NK1.1 T cell development comparable to that of nontransgenic littermates. Characteristically, NK1.1 T cells express intermediate levels of TCR [8](#R8){ref-type="bib"}. Interestingly, in TCR β-loop^−^ transgenic mice, TCR expression on the few remaining NK1.1 T cells is even lower than in control animals; these cells express about four times less TCR than do those in wild-type β-transgenic mice ([Fig. 3](#F3){ref-type="fig"}). Otherwise, NK1.1 T cells in β-loop^−^ transgenic mice express normal levels of CD4 and are CD44^+^CD62 ligand (L)^−^ and IL-2Rβ^+^, as expected for this T cell population [8](#R8){ref-type="bib"}. CD1d, a β~2~ microglobulin--associated molecule required for NK1.1 T cell development [9](#R9){ref-type="bib"} [10](#R10){ref-type="bib"}, is also expressed at normal levels in TCR β-loop^−^ transgenic mice (data not shown).

To determine if development of NK1.1 α/β^+^ T cells could be rescued by the expression of endogenous β chains, as has been described for other TCR-β transgenic mice [19](#R19){ref-type="bib"}, we studied NK1.1 T cell frequency in TCR β-loop^−^ transgenic mice on a β^+/−^ background. We have already observed that in these mice, inhibition of β rearrangements via allelic exclusion is not total, and ∼10--20% of peripheral T cells can express endogenous β chains (data not shown). NK1.1 α/β^+^ T cells expressing endogenous β and β-loop^−^ chains could be distinguished by the Cβ-specific H57 mAb, which cannot stain T cells expressing the mutated β chain ([Fig. 1](#F1){ref-type="fig"}). As shown in [Fig. 4](#F4){ref-type="fig"}, expression of endogenous β chains can rescue NK1.1 T cell development to a certain extent. NK1.1 Cβ^+^ cells appear in the livers of TCR β-loop^−^ transgenic mice on a β^+/−^ background. Yet these cells only account for about one-third of the whole NK1.1 T cell population. The NK1.1 Cβ^−^ T cells are still predominant. There are two populations of NK1.1 Vβ8^+^ cells, which express either intermediate or low TCR levels in TCR β-loop^−^ transgenic mice on a β^1/−^ background. Interestingly, expression of endogenous β chains accounts for most of the NK1.1 T cells expressing intermediate TCR levels. Thus, expression of endogenous β chains did rescue some NK1.1 T cell development and restore TCR expression to intermediate levels. This result strongly suggested that the Cβ FG loop is needed for efficient TCR assembly in NK1.1 T cells.

As most NK1.1 α/β^+^ T cells express an invariant Vα14-Jα281 TCR α chain [20](#R20){ref-type="bib"} [21](#R21){ref-type="bib"}, and the mutant TCR β chain is expressed at normal levels by conventional α/β T cells ([Fig. 1](#F1){ref-type="fig"}) but not by NK1.1 T cells ([Fig. 3](#F3){ref-type="fig"}), we assessed whether the mutant Vβ8.2^+^ TCR β chain could still pair with the Vα14^+^ TCR α chain. TCR^−^ hybridomas were transfected with cDNAs coding for either the wild-type TCR β or β-loop^−^ chain together with the Vα14^+^ TCR α chain or Vα4^+^ TCR α chain (the original partner of the nonmutated β chain) cDNAs. As shown in [Fig. 5](#F5){ref-type="fig"} A, the TCR β-loop^−^ chain clearly pairs with and is expressed on the cell surface with the Vα4^+^ TCR α chain but is barely detectable on the cell surface with the Vα14^+^ TCR α chain. In contrast, the wild-type TCR β chain is expressed on the cell surface with both α chains ([Fig. 5](#F5){ref-type="fig"}). However, the Vα14^+^ TCR is expressed at lower levels than is the Vα4^+^ TCR. This observation may reflect the in vivo situation in which a TCR on NK1.1 T cells is expressed at lower levels than on conventional α/β T cells. To assess whether impaired cell surface expression of the TCR wild-type β and β-loop^−^ chain together with the Vα14^+^ TCR α chain is due to a problem of pairing, TCRs from the transfectants were immunoprecipitated with anti-Vβ8 mAb. As can be seen in [Fig. 5](#F5){ref-type="fig"} B, the TCR α chain can be coimmunoprecipitated with the TCR β chain in all transfectants expressing the TCR on the cell surface. In contrast, the Vα14^+^ TCR α chain cannot be coimmunoprecipitated with the mutant β chain in detectable amounts. This result implies that the Vα14^+^ TCR α chain pairs very poorly with the Vβ8^+^ TCR β chain lacking the Cβ FG loop. It is worth pointing out that in the hybridomas producing the wild-type β and Vα14^+^ chains, many fewer assembled α/β dimers can be immunoprecipitated compared with control Vβ8.2/Vα4 dimers. This latter result suggests that mere physical constraints on the assembly of the β chain with the Vα14^+^ TCR α chain exist and is consistent with the low TCR expression on normal NK1.1 T cells.

Next, we assessed whether the NK1.1 α/β^+^ T cells that do develop in TCR β-loop^−^ transgenic mice express the Vα14^+^ TCR α chain by performing RT-PCR on single NK1.1 CD3^+^ T cells sorted from TCR-β and β-loop^−^ transgenic mice. As summarized in [Table](#T1){ref-type="table"}, the frequency of NK1.1 T cells expressing Vα14 is not significantly decreased in TCR β-loop^−^ transgenic mice in comparison to wild-type TCR-β transgenic animals. One has to keep in mind, however, that there are few NK1.1 T cells in the mutant mice, and these express much lower levels of TCR ([Fig. 3](#F3){ref-type="fig"}). This, together with biochemical data, strongly suggests that in TCR β-loop^−^ transgenic mice, both the impaired development of NK1.1 T cells and their weak TCR expression is due to the physical constraints on the assembly of the β chain lacking the Cβ FG loop with the Vα14^+^ TCR α chain.

We have previously shown that in conventional T cells expressing Vβ8.2, deletion of the Cβ FG loop has no effect on Vα [7](#R7){ref-type="bib"} and Jα repertoire usage (our unpublished data). This result suggested that no drastic conformational changes in the TCR β chain were created by the mutation. However, in this study we clearly show that expression of the Vα14^+^ α chain is sensitive to deletion of the Cβ FG loop. Therefore, deletion of the Cβ FG loop must create some subtle change in TCR β chain conformation. It seems that expression of the Vα14^+^ α chain does not allow much structural flexibility of the TCR, as it is particularly sensitive to TCR β chain conformation. Its expression might impose stringent constraints on α/β assembly. This could at least partially explain why the Vβ repertoire of NK1.1 T cells is relatively limited [30](#R30){ref-type="bib"}. Pairing with the apparently conformation-sensitive Vα14-Jα281 TCR α chain could be the initial pressure on Vβ usage in NK1.1 T cells [19](#R19){ref-type="bib"}. Recently, results obtained by using Vα14-transgenic mice suggested that selection was the main force in shaping the NK1.1 T cell repertoire [31](#R31){ref-type="bib"}. Here we have shown that in addition to selection, differential Vα--Vβ pairing can also potentially influence the NK1.1 T cell diversity. In summary, our data show that subtle changes in the TCR β chain conformation (which do not seem to affect conventional Vβ8.2^+^ α/β TCRs) can substantially alter pairing with the Vα14^+^ α chain and impair NK1.1 T cell development.
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Expression of the Vα14^+^ TCR α Chain by the Remaining NK1.1 T Cells in TCR β-loop^−^ Transgenic Mice

              Number of NK1.1^+^CD3^+^ cells   
  ----------- -------------------------------- -------------
  β           27/27                            20/27 (74%)
  β-loop^−^   30/30                            21/30 (70%)

Liver cell suspensions from TCR-β or β-loop^−^ transgenic mice were double stained with anti-NK1.1 and anti-CD3 mAbs. Double-stained cells were sorted individually to perform RT-PCR as described in Materials and Methods. cDNA encoding the Vα14^+^ TCR α chain was amplified as well as the Vβ8.2^+^ TCR β chain used as positive control for the reaction. Numbers in parentheses represent percentages of Vβ8.2^+^ cells that were Vα14^+^. A representative experiment is shown here.

![T cells expressing the Vβ8.2^+^ TCR β chain lacking the FG loop cannot be stained with the Cβ-specific H57 mAb. LN cell suspensions from TCR-β and β-loop^−^ transgenic mice were stained with anti-CD3 together with anti-Vβ8 or anti-Cβ mAb.](JEM990691.f1){#F1}

![Expression of endogenous TCR β chains can rescue some NK1.1 T cell development. Liver cell suspensions from TCR β, β-loop^−^ transgenic with a β^−/−^ background (β-loop^−^ β-endo^−/−^) or β^−/+^ background (β-loop^−^ β-endo^−/+^) were triple stained with anti-NK1.1, anti-Cβ, and anti-Vβ8 mAbs. Numbers in dot plots are percentages of the total adjacent gated dots. Histograms represent expression of Cβ (in β-loop^−^ transgenic mice with a β^−/−^ or β^−/+^ background) for the NK1.1^+^ gated population expressing either intermediate (NK1.1^+^Vβ8^int^) or low levels of TCR (NK1.1^+^Vβ8^low^).](JEM990691.f4){#F4}

![Decreased amount of NK1.1 T cells in TCR β-loop^−^ transgenic mice. Cell suspension from thymi previously depleted of CD8^+^ cells and livers from nontransgenic littermates (WT) or TCR-β or β-loop^−^ transgenic mice were double stained with anti-NK1.1 together with anti-Cβ (to stain all T cells in WT mice) or anti-Vβ8 (which stains all T cells in transgenic mice) antibodies. Numbers express the percentages of total adjacent gated dots.](JEM990691.f2){#F2}

![The remaining NK1.1 T cells in TCR β-loop^−^ transgenic mice have a normal phenotype. Liver cell suspensions from TCR-β or β-loop^−^ transgenic mice were triple stained with anti-NK1.1, anti-Vβ8, and either anti-CD4 or anti-CD44 or anti-CD62L or anti--IL-2Rβ mAbs. Histograms represent NK1.1^+^Vβ8^+^ gated events. Numbers in parentheses represent the mean fluorescence intensity of Vβ8 staining. Negative controls of Vβ8 staining are shown (dashed lines).](JEM990691.f3){#F3}
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Inefficient pairing of the Vα14^+^ TCR α chain with the Vβ8.2^+^ TCR β chain lacking the complete Cβ FG loop. (A) TCR^−^ hybridomas were transfected with either the Vβ8.2^+^ wild-type TCR β or β-loop^−^ chain, together with the Vα14^+^ TCR α chain or Vα4^+^ TCR α chain. Stable transfectants were stained with biotinylated anti-CD3 mAb, followed by streptavidin--allophycocyanin. Stainings of cells transfected with only the TCR β or β-loop^−^ chain are shown as controls. Numbers in parentheses represent the mean fluorescence intensities of CD3 staining. (B) TCRs of transfected hybridomas or Vβ8^+^ T hybridoma control (A5) (8.0, 8.0, 10.0, 14.0, 20.0, 20.0, and 8.0 × 10^7^ cells per lane, respectively, from left to right) were immunoprecipitated with anti-Vβ8 mAb (F23.1), electrophoresed on a 4--12% gel in reducing conditions, and blotted with anti-Cα (H58) or anti-Vβ8 mAb as described in Materials and Methods. Numbers represent protein molecular mass (kD).
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